Génomique – CIML

Members

About

Créée en 2019, la plateforme de génomique du CIML met à disposition des chercheurs et personnels scientifiques de l’institut des technologies de pointe en transcriptomique et en génomique, ainsi qu’une expertise dédiée pour accompagner leurs projets. La plateforme est composée du responsable scientifique Pierre Milpied (Directeur de Recherche Inserm) et Laurine Gil (Ingénieure d’Etude CNRS).

En 2024, la plateforme a obtenu le label de qualité « Plateforme Aix-Marseille » pour une durée de trois ans, délivré par Aix Marseille Université, l’Inserm et le CNRS.

The missions of the CIML Genomics platform are:

Provide and maintain the necessary equipment: The genomics platform provides material and technological support by making various equipment available.
Train users : the platform offers training to users, allowing them to master the techniques necessary for their scientific projects.
Supporting experiments : the platform offers experimental support to assist users during complex manipulations, thus ensuring the quality and precision of experiments.
Develop new methods : continuous technological monitoring allows us to offer the most recent innovations and make available protocols based on bulk RNA-seq or single-cell RNA-seq technologies.
Assist with experimental design : the platform helps users to best define their experimental design, in close collaboration with the CIML CB2M (Computational Biology, Biostatistics and Modeling) platform.
Carry out projects : the platform offers to fully support certain genomics experiments to meet the specific needs of research projects (library preparation, sequencing).

Our Services

The genomics platform supports users throughout their projects, from experimental design to sequencing data acquisition, ensuring scientific rigor and technical quality. This support is offered through various services:

Experimental design : the platform provides advice and support in defining experimental design, in close coordination with all the other CIML platforms involved.
Training and experimental support : la plateforme assiste les utilisateurs dans la réalisation d’expérimentations complexes, garantissant la fiabilité et la reproductibilité des expériences.
Access to genomics equipment : the platform provides a wide range of instruments (thermal cyclers, qPCR devices, Agilent TapeStation, Chromium X).
Preparation of single-cell RNA-seq libraries : the platform supports the preparation of single-cell RNA-seq libraries at the request of project leaders.
High-throughput sequencing : the platform ensures the sequencing of libraries on the Illumina NextSeq 2000 sequencer.

Our Technologies

Nous disposons d’une expertise avancée et des équipements nécessaires pour réaliser des analyses multi-omiques sur cellules uniques après capture en goutelettes (technologie 10x Genomics) : single-cell RNA-seq, CITE-seq, single-cell BCR-seq, single-cell TCR-seq.

Nous sommes aussi experts de la technologie d’analyse multi-omique sur cellules uniques FB5P-seq (FACS-based 5′-end sequencing), développée au CIML, et permettant l’analyse intégrative (phénotype, transcriptome, répertoire BCR ou TCR) de cellules rares triées par FACS.

We provide the necessary equipment for the preparation and quality control of sequencing libraries for any type of protocol, and we perform the sequencing of compatible libraries on our Illumina NextSeq2000 high-throughput sequencer.

Nous disposons d’un parc de 4 équipements de PCR quantitative en temps réel, compatibles avec les formats 96-puits ou 384-puits.

Training

The genomics platform provides training activities at two levels:

Within the CIML, by providing staff training in techniques related to the preparation of single-cell RNAseq libraries.
Nationally, with Inserm training “Single-cell RNAseq analyses”, organized once or twice a year in collaboration with the CIML CB2M platform.

News

Lymphome B : une carte cellulaire inédite pour mieux prédire l'évolution de la maladie

Deux équipes de recherche du Centre d’Immunologie de Marseille Luminy, en collaboration avec l’industriel Bristol Myers Squibb, ont établi la […]